SWOG Study S1605 Page
This page is for reference and assistance to study sites participating in SWOG's clinical trial S1605, "Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer."
Why is this study being done?
The purpose of this study is to test the effects of the investigational drug atezolizumab in stopping non-muscle invasive bladder cancer from coming back and progressing to muscle invasive bladder cancer. Atezolizumab is not approved by the FDA for treatment of this type of cancer. Atezolizumab is a type of immunotherapy (a drug that helps your body to fight a specific part of each cancer cell). About 148 people will take part in this study.
More information about the study?
- Members version of the protocol abstract page (from which the full protocol is available): S1605 Protocol Abstract Page. Staff from non-SWOG sites can find the full protocol and related materials by logging in to the CTSU site.
- For general questions about the study, select "Protocols" as the subject area on the Contact Us page and we will get in touch with you.
Training, Recruitment and Retention Materials
Staff Materials
- FAQs for Staff and Investigators (PDF): These are for staff use only to clarify procedures and/or protocol statements. They will be updated as protocol changes are made or as new questions are added.
- S1605 Protocol Card March 2017 (PDF): If you received 4x6 laminated protocol cards, you may distribute them to your local doctors to carry in their lab coat pockets. These cards are designed to encourage referrals and are reminders of S1605 eligibility criteria. If you don't have 4x6 cards, you may use the 8.5x11 document to post where your physicians/surgeons gather to discuss cases. You may add a label on the card or document with the contact information for the staff person at your site.